EN
A contribution of B cells and autoantibodies has been demonstrated in MS leading to interest in the use of such autoantibodies as diagnostic or prognostic markers and as a basis for immunomodulatory therapy. ELISA and Western blotting fail to detect reactivity against epitopes displayed by native antigens expressed on myelin sheats. We describe a cell-based assay that specifi cally identifi es serum antibodies directed against myelin autoantigens: MBP, PLP and MOG. The method detects antibody binding to recombinant antigens in their native conformation on MBP, PLP or MOG transfected mammalian (hamster ovary) cells. 36 patients with relapsing-remitting MS diagnosed according to criteria of Mc Donald were recruited. Age 38.2 and duration of the disease 7.1. Serum anti-MBP, anti-PLP and anti MOG IgG autoantibodies were detected in MS patients and 35 healthy donors by FACS analysis. Compared with healthy controls the titers of IgG autoantibodies directed against membrane-bound recombinant myelin antigens were most signifi cantly increased for PLP, no quite signifi cant for MBP and not signifi cant for MOG. The titers of anti-MBP antibodies were low in contrast to high titers of anti-MOG antibodies in both groups suggesting a nonspecifi c binding. The cell-based assay detection of autoantibodies directed against recombinant myelin antigens could be a useful tool providing the serological markers in diagnosis and progression of MS. Indeed, it could allow to obtain molecular characteristics of disease in each patient in term of an antibody response against certain myelin and non-myelin antigens. We have shown that in RRMS patients elevated level of serum antibodies against PLP is signifi cant, what should be considered in search for specific immunomodulatory therapy in MS.